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SerB2 is an essential phosphoserine phosphatase (PSP) that has been shown to be involved in 
Mycobacterium tuberculosis (Mtb) immune evasion mechanisms, and a drug target for the 
development of new antitubercular agents. A highly similar (91.0 %) orthologous enzyme 
exists in the surrogate organism Mycobacterium marinum (Mma) and could have acquired 
similar properties. By homology modeling, we show that the two PSPs are expected to 
exhibit almost identical architectures. MmaSerB2 folds into a homodimer formed by two 
intertwined subunits including two ACT regulatory domains followed by a catalytic core 
typical of HAD (haloacid dehalogenase) phosphatases. Their in vitro catalytic properties are 
closely related as MmaSerB2 also depends on Mg2+ for the dephosphorylation of its substrate, 
O-phospho-L-serine (PS), and is most active at neutral pH and temperatures around 40°C. 
Moreover, an enzyme kinetics study revealed that the enzyme is inhibited by PS as well, but 
at lower concentrations than MtbSerB2. Substrate inhibition could occur through the binding 
of PS in the second active site and/or at the ACT domains interface. Finally, previously 
described beta-carboline MtbSerB2 inhibitors also decrease the phosphatase activity of 
MmaSerB2. Altogether, these results provide useful information when M.marinum is used as 
a model to study immune evasion in tuberculosis.  
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Mycobacterium marinum (Mma) is a free-living nontuberculous mycobacterium found 
worldwide in fresh-, salt- and brackish water [1]. The organism mostly causes tuberculosis-
like infection in fish and amphibians but can also infect humans by entering the skin through 
superficial wounds [2,3]. Within a few weeks after exposure, infected individuals develop 
purulent granulomatous skin lesions at the site of the inoculation (usually the hands) [4,5]. 
The disease is known as the “fish tank granuloma” and, even if quite rare, is a risk for anyone 
handling fish or exposed to improperly chlorinated waters [6]. Outbreaks of M. marinum can, 
therefore, be a major concern for zebrafish research facilities, both in terms of staff and fish 
[7].  
Because of the similarities in the pathologies they cause and their very close genetic 
relatedness, M. marinum has been widely used as a surrogate organism for M. tuberculosis 
(Mtb) and model to study the pathogenesis of tuberculosis in humans [8–12]. The two 
macrophage pathogens share over 3000 orthologous genes with an average amino acid 
identity of 85% and very similar genetic programs in terms of virulence and protection 
[13,14]. Moreover, the classification of M. marinum as a BSL2 organism and its 
comparatively rapid growth make it easier to manipulate in the laboratory than its counterpart 
[15]. 
Most organisms synthesize L-serine de novo via the so-called “phosphorylated pathway”. In 
this biosynthetic route, a phosphoglycerate dehydrogenase (PGDH EC 1.1.1.95) first converts 
the glycolytic intermediate 3-phosphoglycerate to 3-phosphohydroxypyruvate, which is in 
turn transformed to O-phospho-L-serine (PS) by a phosphoserine aminotransferase (PSAT, 
EC 2.6.1.52). The third and last step then involves a phosphoserine phosphatase (PSP, EC 





tuberculosis, the three enzymes are respectively encoded by the essential genes serA1, serC, 
and serB2 [18,19]. While MtbPGDH SerA1 and MtbPSAT SerC appear to play a purely 
metabolic role, MtbPSP SerB2 also acts as an effector protein in infected macrophages 
[20,21]. As demonstrated by Shree et al. [21], the interaction of MtbSerB2 with various host 
proteins elicits cytoskeleton rearrangements, inhibition of apoptotic pathways, and down-
regulation of inflammatory cytokine IL-8. These effects are reversed by Clofazimine (CFZ), a 
riminophenazine drug that inhibits MtbSerB2 phosphatase activity. Several other MtbSerB2 
inhibitors have been identified by various groups, including ours, thereby confirming the 
druggability of the enzyme [22–24]. MtbSerB2 is now considered a promising therapeutic 
target for the treatment of tuberculosis, which continues to be a major public health issue.  
Given the very close genetic relationship between the two pathogens, it is not surprising that 
M. marinum also possesses the enzymes of the phosphorylated pathway [13]. The 
orthologous PSPs exhibit a high sequence similarity (91.0 %) and it could be possible that 
MmaSerB2 has also gained effector functions allowing the modulation of host immune 
response. In this work, we report for the first time a biochemical characterization of 
MmaSerB2 and a comparison with its close homolog MtbSerB2.  
MATERIALS AND METHODS  
In silico analysis tools  
Multiple sequence alignment was obtained using MultAlin [25] and the related figure was 
prepared using ESPript 3.0 [26]. Sequence identity values were calculated using the Sequence 
Manipulation Suite [27]. The figures of the 3D model were prepared using PyMOL 







Expression and purification of MmaSerB2 
Escherichia coli strain BL21 (DE3) was transformed with a pAVA0421 plasmid encoding for 
an N-terminal His6-tagged MmaSerB2 under control of the T7 RNA polymerase promoter. 
The plasmid contains the ampicillin resistance gene (ampR). Protein expression and 
purification were carried as described in reference [24]. The concentration of the tagged 
protein was determined spectrophotometrically at 280 nm using 11585 M-1 cm-1 as the 
extinction coefficient and 45.83 kDa as the molar mass.  
Enzymatic activity assay, inhibition, and kinetics studies  
Enzyme activity was measured in an end-point phosphatase assay, using malachite green and 
ammonium heptamolybdate at low pH to colorimetrically determine the amount of inorganic 
phosphate (Pi) released during the hydrolysis of PS. Reactions were carried with 0.2 mM PS 
in Tris-HCl buffer according to the standard test conditions and protocol detailed in reference 
[24]. The standard test buffer (pH or 5 mM metal ion as chloride salt) or temperature of the 
assay were varied in order to study each parameter independently. For native kinetics 
measurements, 200 µL-reactions containing 1 pmol enzyme and 0 to 7.5 mM PS in standard 
test buffer were allowed to proceed for 10 min at 37°C. Initial velocities were reported as the 
amount of Pi released per microgram of enzyme per minute. For inhibition assays, reactions 
were carried with 0.4 mM PS, 2% DMSO and 0 (DMSO control), 10, or 100 µM inhibitor.  
Evaluation of kinetic parameters  
The kinetic parameters of MmaSerB2 were determined by fitting the model described by 
LiCata and Allewell [28] to the experimental velocity curves. This model (equation (1)), 
based on a modified Hill equation, accounts for cooperative substrate binding as well as 




















𝑥  (1) 
v is the initial velocity (nmol µg-1 min-1) at substrate concentration [S] (mM), Vmax is the 
maximal velocity (nmol µg-1 min-1), KM  is the Michaelis-Menten constant (mM), Vi is the 
final velocity at infinite substrate concentration (nmol µg-1 min-1), Ki is the substrate 
inhibition constant (mM) representing the concentration of inhibitor (substrate) required to 
decrease Vmax by half, n is the Hill coefficient reflecting cooperativity in substrate binding 
and x is another Hill coefficient taking into account that substrate inhibition may also be 
cooperative. The value of x must be fixed to obtain convergence. We have empirically 
determined the value of x giving the best fit. The smallest standard error of the estimate was 
obtained with x = 5. The values of Vmax, Vi, KM, Ki, and n were calculated by non-linear 
regression based on equation (1) using GraphPad Prism 6 (GraphPad Software, La Jolla 
California USA). 
RESULTS AND DISCUSSION 
In silico analysis of MmaSerB2  
The phosphoserine phosphatase SerB2 from the M strain of M. marinum (UniProt accession 
number B2HHH0) has a length of 411 aa and a mass of 43443 Da. Two other genes 
designated as serB and serB1 in the genome of the M strain are also listed as PSPs in the 
ENA database (accession numbers ACC43554.1 and ACC39293.1). The gene products 
MmaSerB (285 aa) and MmaSerB1 (303 aa) are shorter and share respectively 23.1 % and 
29.8 % sequence similarity with MmaSerB2, and 48.4 % similarity among themselves. 
Transposon mutagenesis experiments have identified MmaSerB1 as most likely essential for 
the survival of M. marinum strain E11 [29] while its M. tuberculosis H37Rv orthologue 





which MmaSerB2 shares 91.0 % similarity and 85.9 % identity. A Pfam search confirmed 
that MmaSerB2, like MtbSerB2, is a haloacid dehalogenase (HAD)-like hydrolase that 
possesses 2 extra N-terminal ACT domains (Pfam 13740 and 01842). These domains, found 
in some PSPs only, are known to regulate enzyme activity by binding amino acids [30,31]. 
The multiple sequence alignment shown in Figure 1 illustrates the high similarity of 
mycobacterial PSPs and highlights the presence of the 4 signature motifs of HAD 
phosphatases in MmaSerB2 [32,33]. The ACT domains, absent in human PSP, are also highly 
conserved and all residues that are known to be important for binding of L-serine in 
MtbSerB2 [22,34] and SerB from M. avium (MavSerB, based on the surrounding residues in 
PDB structures 5JLR and 5JLP) are present in MmaSerB2. MavSerB (PDB 3P96, 83.4% 
sequence identity) was employed as a template to model the 3D structure of MmaSerB2 using 
SWISS-MODEL [35]. As expected, the homology model (Figure 2A) exhibited three distinct 
domains: the catalytic core, arranging into a Rossmannoid fold typical of HAD phosphatases 
topped with a C1 cap module [32], and two α/β sandwiches forming the ACT domains, 
connected by a loop of about 10 aa. MmaSerB2 is also predicted to be a homodimer, in which 
the monomeric subunits swap their N-terminal ACT domain (Figure 2B). The 
superimposition of MmaSerB2 model with the structures of MavSerB 3P96 and MtbSerB2 
modeled in the same way led to root mean square deviations of 0.103 and 0.057 Å, 
respectively. These results confirm that the three enzymes are expected to share almost 
identical architectures. According to the models, all the residues that differ between 
MmaSerB2 and MtbSerB2 are found at the surface, and the organization of the active site is 
perfectly conserved (Figure S1).   
Effects of selected metal cations, pH and temperature on MmaSerB2 activity 
The phosphatase activity of MmaSerB2 was measured at pH 7.4 and 37°C in the presence of 





shown in Figure 3A, MmaSerB2 activity was significantly different from zero only in the 
presence of Mg2+, Mn2+, or Ca2+. The highest activity was observed in presence of Mg2+ and 
the activities in the presence of Mn2+ and Ca2+ were respectively 37% and 7% of that seen 
with Mg2+. The same trend is reported for MtbSerB2 [22,23]. Together with the fact that the 
enzyme was inactive in the metal ion-free buffer, these results indicate that MmaSerB2 is 
dependent on divalent metal cations and most certainly uses Mg2+ as an obligatory cofactor. 
This observation is a common feature of all HAD phosphatases [32].  
The pH dependence of MmaSerB2 phosphatase activity in Tris-HCl buffer at pH values 
ranging from 7.0 to 9.0 and 37°C is shown in Figure 3B. The optimum pH for the 
dephosphorylation of PS was observed around 7.6, with the enzyme showing 92% and 98% 
of its maximum activity at pH 7.4 and 7.8, respectively. The enzyme was active over the 
entire tested pH range with relative activities over 70% at pH 7.0 and pH 8.2. Beyond this pH 
value, the activity decreased almost linearly to reach 44% relative activity at pH 9.0. These 
results are in line with the findings published earlier for MtbSerB2 [22,23].  
The optimal temperature for MmaSerB2 phosphatase activity was investigated in the range 
25-60°C. As shown in Figure 3C, the optimal temperature was found to be 42°C. At 25°C, 
the enzyme showed 46% of its maximum activity. The enzymatic activity increased with the 
reaction temperature up to 42°C, a ten degree rise in temperature almost doubling the 
activity. The temperature range in which MmaSerB2 was most active (over 80% relative 
activity) extended from 34 to 44°C. Above 50°C, the activity decreased sharply with the 
reaction temperature. The enzyme showed only 6% relative activity at 54°C and was totally 
inactive at 60°C. Comparatively, the optimal temperature described by Yadav, Shree et al. for 
MtbSerB2 is 37°C but no activity values were reported between 40 and 50°C in their work 






Kinetic characterization of native MmaSerB2  
To evaluate the kinetic properties of MmaSerB2, its phosphatase activity was measured at PS 
concentrations ranging from 0 to 7.5 mM. The plot of initial velocity against PS 
concentration is shown in Figure 3D. The shape of the curve clearly indicated partial 
inhibition by the substrate above a concentration of 3 mM, as the velocity increased to a 
maximum and then decreased to a plateau. This observation was not surprising since Grant 
demonstrated that the orthologous MtbSerB2 is also inhibited by PS using a similar assay 
[34]. The usual kinetic parameters were derived from fitting equation (1) to the experimental 
data and reported in Table 1, along with MtbSerB2 kinetic parameters from other work for 
comparison [24,34]. While kcat values were of the same order of magnitude for both enzymes, 
the KM value was 2.6 to 5 times higher for MmaSerB2. This observation could mean that the 
latter enzyme is somewhat less affine for PS than its Mtb ortholog. The parameters n, Ki and 
Vi were also calculated for MmaSerB2. The inhibited rate (Vi = 5.40 ± 0.23 nmol min
-1 µg-1) 
indicated that, at high PS concentrations, the rate became 2.8 times slower than the maximum 
rate exhibited by the enzyme. It was also observed that MmaSerB2 showed no significant 
cooperativity in substrate binding (n = 1.1 ± 0.1) but was cooperatively inhibited by PS at 
4.4-fold KM concentrations (Ki = 4.32 ± 0.21 mM). Compared to Grant’s results, MmaSerB2 
appeared to be more sensitive to substrate inhibition than MtbSerB2 (Ki = 23 ± 5 mM [34]).  
Enzyme Work KM (µM) Vmax  





MmaSerB2 Our group 985 ± 128 15.3 ± 1.3 11.7 ± 0.9 1.19  
MtbSerB2 Our group [24] 195 ± 4 15.4 ± 0.1 11.2 ± 0.1 5.72 






Globally, this kinetic behavior is typical of a multisite (homodimeric) enzyme inhibited by 
saturating concentrations of its substrate [36]. The shape of the curve indicates that 
MmaSerB2 is more catalytically active when only one of its two active sites is occupied by 
PS (low concentrations). At high PS concentrations, the velocity decreases as a major fraction 
of the enzyme is converted to the less active doubly occupied MmaSerB2. Furthermore, it 
would be possible that PS also interacts at an allosteric site. Such an inhibitory site could be 
found at the interface of ACT1 and ACT2 domains, where L-serine is known to bind and 
exert a regulatory effect in MtbSerB2 and MtbPGDH [34,37]. This hypothesis is further 
supported by the fact that MtbSerB2 mutant G18A/G108A presents no substrate inhibition, as 
shown by Grant [34]. The two glycine residues are, indeed, required for efficient L-serine 
binding in ACT domains [22,31]. If PS can also interact at this site, mutation G18A/G108A 
in MtbSerB2 would, as observed, prevent the binding event and hence substrate inhibition. A 
docking experiment using Glide (Schrödinger, LLC, New York) confirmed that PS fits in the 
L-serine binding site of MmaSerB2 model and could interact with the orthologous G20 
residue, as well as with D17, T22, and I126 (Figure S2). 
Inhibition of the phosphatase activity of MmaSerB2 by CFZ and harmine derivatives 
The effect of CFZ and our previously described trisubstituted harmine derivatives [24] 
(Figure S3) was tested on MmaSerB2 phosphatase activity. As shown in Figure 3E, 
compounds 91, 95, and 124 almost completely abolished enzyme activity at 10 µM. The 
effect was observed to the same extent for the three inhibitors. On the other hand, CFZ and 
derivative 88 had little effect at 10 µM. However, we observed a significant reduction in 
phosphatase activity when the inhibitors concentration was increased to 100 µM in the assay. 
In these conditions, the residual activity dropped to 2.3% in the case of CFZ and to 20% for 





an inhibitory effect on MmaSerB2 and the trend was in good agreement with that observed 
for MtbSerB2 [21,24]. 
CONCLUSION 
The results of this work support that, like MtbSerB2, MmaSerB2 is a Mg2+-dependent, 
mesophilic HAD-like phosphatase that is most active near neutral pH. With the two 
orthologues sharing a very high sequence similarity and an almost identical architecture, as 
predicted by homology modeling, these results could be expected. Both PSPs are inhibited by 
their substrate, O-phospho-L-serine, and the kinetic behavior of MmaSerB2 was shown to be 
consistent with a mechanism of partial uncompetitive substrate inhibition that supports the 
homodimer model. The mechanism could also involve the interaction of PS at the ACT 
domains interface. While they showed comparable maximal catalytic rate and affinity for PS, 
MmaSerB2 was more sensitive to substrate inhibition (lower Ki) than MtbSerB2. Finally, this 
work led to the identification of clofazimine and trisubstituted harmine derivatives as 
inhibitors of MmaSerB2 phosphatase activity. 
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Table 1. Kinetic parameters of MmaSerB2 and MtbSerB2 for the dephosphorylation of O-
phospho-L-serine.   
Figure 1. Multiple sequence alignment of M. marinum SerB2 (Uniprot: B2HHH0) ; M. 
tuberculosis SerB2 (Uniprot: O53289) ; M. avium SerB (PDB: 3P96) and H. sapiens PSP 
(Uniprot: P78330). The secondary structure elements of MavSerB are shown in the first line. 
Strictly conserved residues are highlighted in red and highly conserved residues are shown in 
red font. ACT1/ACT2 and C1 cap module domains are boxed in cyan and grey respectively. 
Motifs 1 (hhhDxDxT(L/V)h), 2 (hh(S/T)), 3 and 4 (K18-30(G/S)(D/N)x3-4(D/E)), where h is an 
hydrophobic residue and x is any residue, are boxed in dark blue. Residues important for L-
serine binding in MtbSerB2 and MavSerB are boxed in black. 
Figure 2. A) Structure of MmaSerB2 modeled by homology on the basis of M. avium SerB 
structure (PDB 3P96). The individual domains are labelled. Active site residues are shown in 
red. Residues predicted to be important for L-serine binding are labelled and shown in pink.   
B) Homodimeric assembly of homology-modeled MmaSerB2. The second monomer is 
shown in orange. One of the two predicted L-Ser binding sites at the interface of ACT1 and 





Figure 3. Effect of selected reaction conditions on MmaSerB2 phosphatase activity during 
the dephosphorylation of O-phospho-L-serine (PS). Data depicted are averaged from three 
independent experiments ± S.E. A) Influence of selected metal cations. B) Influence of the 
reaction buffer pH. C) Influence of the reaction temperature. D) Variation of the initial 
velocity as a function of PS concentration. Best fit of equation (1) is shown as a solid line. E) 
Influence of Clofazimine (CFZ) and trisubstituted harmine derivatives (88, 95, 91, and 124) 
in presence of 2% DMSO. The activity of MmaSerB2 in presence of 2% DMSO and no 
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